Reactogenicidad e inmunogenicidad

31/08/2006

image_pdfimage_print

Respuesta del Experto a …

Reactogenicidad e inmunogenicidad

Pregunta

En relación con las 2 vacunas hexavalentes comercializadas en españa, y dadas las noticias (EMEA- 28 de Abril 2003), sobre reacciones adversas graves, quiero conocer los últimos datos sobre INMUNOGENICIDAD y REACTOGENICIDAD de las mismas,y la posibilidad de interferencias inmunológicas entre los distintos antíegenos que componen las mismas.

Gracias.

Luis Ortigosa
Hospital Universitario Ntra Sra de Candelaria.Tenerife

Respuesta del Dr. José Antonio Navarro Alonso (02 de julio de 2003)

Los últimos datos sobre reacciones adversas graves de las vacunas hexavalentes se encuentran disponibles (informe de la E.M.E.A.) en la web de la Asociación Española de Vacunología, en su sección NOTICIAS DESTACADAS del mes de mayo 2003 (#). Los datos de inmunogenicidad de sus componentes publicados en revistas revisadas por pares o presentados en congresos, hasta la fecha, son:

. Saenger R, Meurice F, Schuerman L. Comparison of the immunogenicity od diphteria-tetanus-acellular pertussis-IPV-HBV/HIB with diphteria-tetanus-acellular pertussis-HBV-IPV-HIB given as a primary vaccination course at 2, 4 and 6 months of age. 21st Annual Meeting of the European Society for Paediatric Infectious Diseases. Giardini Naxos, Taormina. April 9-11, 2003. Abstract book number: 283

. Mallet E, Fabre P, Pines E, Salomon H, Staub T, Schödel F et al. immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr Infect Dis J 2000;19:1119-1127

. Schmitt H, Knuf M, Ortiz E, Sänger R, Uwamwezi M, Kaufold A. primary vaccination of infants with diphteria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 2000;137:304-312

. Mallet E, Staub T, Schödel F, Chryssomalis G, Hoffenbach A, Scemama M. safety and immunogenicity od a booster dose of the liquid hexavalent vaccine (DTPa-IPV-hib-HB, Hexavac) in 12-18 months-old toddlers. 19th Annual Meeting of the European Society for Paediatric Infectious Diseases. Istambul, March 26-28, 2001

. Crovari P, Zepp F, Dentico P, Habermeh P, Huff J, Schuerman L. Immunogenicity and reactogenicity of combined DTPA-HBV-IPV and HIB vaccines given at 3, 5 and 11 months of age. 9th Annual Meeting of the European Society for Paediatric Infectious Diseases. Istambul, March 26-28, 2001

. Liese J, Stojanov S, Berut F, Minini P, Harzer E, Jow S et al. Large scale safety studies of a liquid hexavalent vaccine (D-T-acP-IPV-PRPT-HBs) administered at 2, 4 6 and 12-14 months of age. Vaccine 2002;20:448-454

. Avdicová M, Prikazsky V, Hudecková H, Schuerman L, Willens P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination sechedule. Eur J Pediatr 2002;161:581-587

. Omeñaca F, García-Sicilia J, Boceta R, García-Corbeira P, Romero A, Lopez G et al. Immunogenicity of a combined DTPa-HBV-IPV/Hib vaccine in preterm infants (<37 weeks) as a primary vaccination course. 3rd World Congress of Pediatric Infectious Diseases-WSPID. Santiago, Chile, November 19-23, 2002. Abstract Book: 46

. Crovari P, Durando P, Sticchi L, Soncini R, Zepp F, HAbermehl P et al. Evaluation of the immunogenicity and reactogenicity of a new 6-valent (DTPa-HBV-IPV/Hib) vaccine. 3rd World Congress of Pediatric Infectious Diseases-WSPID. Santiago, Chile, November 19-23, 2002. Abstract Book: 46

. Saenger R, Maechler G, Scuerman L. Safety of a booster dose of DTPa-HBV-IPV/Hib compared to concomitant administration of DTPa-IPV/Hib and HBV vaccines. 3rd World Congress of Pediatric Infectious Diseases-WSPID. Santiago, Chile, November 19-23, 2002. Abstract Book: 46

. Halperin S, Langley J, Helsey T, Zappacosta P, Ridley D, Hoffenbach A et al. Safety and immunogenicity of two formulations of a hexavalent diphteria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15-18 month-old children. The Sixth Annual Conference on Vaccine Research. Arlington, Virginia. May 5-7, 2003. Abstract number: S21

image_pdfimage_print

Artículos relacionados


Subir al menú